Document is current
Any future updates will be listed below
-
Authors
Drljevic-Nielsen, Aska
Rasmussen, Finn
Nielsen, Patricia Switten
Stilling, Christina
Thorup, Kennet
Mains, Jill Rachel
Madsen, Hans Henrik Torp
Donskov, Frede
-
Funding
Funding for this research was provided by:
Philips
Novartis
Roche
Ipsen
The Maersk Foundation
The Health Research Foundation of Central Denmark
The Memorial Foundation of Eva and Henry Fraenkel
- License Information
-
More Information
Article History
Received: 12 March 2021
Accepted: 1 July 2021
First Online: 30 July 2021
Declarations
:
: Trial Registration: Darenca-1 study was approved by the Danish Ethics Committee (URL: ) (case no. 1-10-72-472-12) on the 23rd of June 2009, the Danish Data Protection Agency (URL: ) (journal no. 2012-41-0897) on the 25th of May 2009, and the Danish Medicines Agency (URL: ) (journal no. 2612-4042) on the 1st of July 2009; the study was registered at (identifier NCT01274273).Approval by the Regional Ethics Committee, the Danish Medicines Agency, and The Danish Data Protection Agency was granted, and written informed consent was obtained before inclusion started.
: Not applicable.
: A. Drljevic-Nielsen reports receiving research grants from Ipsen, the Maersk Foundation, and the Health Research Foundation of Central Denmark Region, and conference travels from Pfizer and Ipsen. F. Donskov reports receiving research grants from Ipsen, Pfizer, MSD, and the Health Research Foundation of Central Denmark Region. JR. Mains reports receiving research grants from the Memorial Foundation of Eva and Henry Fraenkel and the Health Research Foundation of Central Denmark Region and conference travels from Pfizer. No potential conflicts of interest were disclosed by C. Stilling, P. Switten Nielsen, F. Rasmussen, and K. Thorup.
